Life Science Compliance Update

The pharmaceutical and medical technology industries appear to show marked transfer of value variations in this year’s Open…

The new Cardiovascular Systems, Inc. False Claims Act settlement has some in the industry wondering why CSI settled for such a…

Recent arrests have once again left the pharmaceutical world wondering how many times do the same lessons have to be learned?…

The Office of Inspector General ("OIG") of the U.S. Department of Health and Human Services ("HHS"), has recently updated its…

Kurt Stitcher, Senior Compliance Consultant The U.S. Department of Justice's FCPA Pilot Program is nominally designed to…

The FDA and the GAO both released data on the FDA's performance in medical device regulation over the last several years. This…

In late March 2016, Novartis Pharmaceuticals Corp. (NPC) and the U.S. Department of Justice and the State of New York…

The price of prescription drugs has created much controversy in recent years. This article examines why the…

Europe adopted a new Code of Ethical Business Practice late last year. This article explores the purpose of the new Code,…

Recent legal cases have highlighted the important issue of whether or not attorney-client privilege attaches to internal…